camrelizumab,albumin-bound paclitaxel
jiangsu hengrui pharmaceuticals
['advanced l', 'key,note,52', 'nsclc', 'keynote,54', 'sclc', 'ca,022,i', 'check,mate,004', 'check,mate,003', 'ca,022,1', 'key,note,45', 'key,note,62', 'key,note,42', 'check,mate,752', 'prednisone', 'cisplatin', 'nivo', 'paclitaxel', 'ca,022,001', 'carboplatin', 'combine,egfr,1', 'gastric', 'esophageal', 'thoracic', 'keynote,91', 'pembro', 'apatinib', 'escort-1', 'keynote-407', 'key,note,48', 'nivolumab', 'check,mate,901', 'key,note,042', 'combine,egfr,i', 'oreo', 'biomarker', 'melanoma', 'fluoro', 'albumin,bound,paclitaxel', 'check,mate,002', 'dance', 'rcc,(-irccs),(-srcc),(-urcc)', 'check,mate,951', 'key,note,24', 'key,note,045', 'lung', 'aster,70', 'check,mate,577', 'solid tumor', 'camrelizumab', 'key,note,57', 'valent ,(-prevalent)', 'marker ']
fascinating report from jie lei regarding their phase ii trial of camrelizumab w/albumin-bound paclitaxel and cisplatin in resectable stage iiia and iiib(t3n2) nsclc at #esmoimmuno22. read about camrelizumab in esophageal squamous cell carcinoma in #jitc: 
#JITC is the official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. Editor-in-Chief: Pedro J. Romero, MD.